16+
Major trials tracked
A triple agonist against a dual agonist in metabolic disease
Retatrutide vs tirzepatide: trial pipelines compared
A side-by-side view of the retatrutide and tirzepatide clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for retatrutide and 16+ for tirzepatide. Add up to three more drugs to widen the comparison.
retatrutide (16) vs tirzepatide (16)16 active2017–2032
retatrutidetirzepatide
'17
'19
'21
'23
'25
'27
'29
'31
retatrutide
A Study of LY3437943 in Participants With Type 2 DiabetesP2
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightP2
TRIUMPH-3P3
TRIUMPH-1P3
TRIUMPH-2P3
TRIUMPH-4P3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)P3
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)P3
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)P3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)P3
TRIUMPH-5P3
TRIUMPH-6P3
TRIUMPH-7P3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)P3
TRIUMPH-9P3
GZBFP2
tirzepatide
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes MellitusP2
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesP3
SURPASS-3P3
SURPASS-5P3
SURMOUNT-OSAP3
SURPASS-CN-INSP3
TREASURE-CKDP2
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesP3
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightP2
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightP3
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)P3
REIMAGINE 5P3
STOP KNEE-OAP4
STAY-LEANP4
GYMINDAP2
LOCITTP2
Upcoming readouts
13 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
retatrutideGLP-1 & incretin therapies
13
Phase 3 trials
2
Actively recruiting
Oct 2026
Next phase 3 readout
tirzepatide (Mounjaro / Zepbound)GLP-1 & incretin therapies
16+
Major trials tracked
9
Phase 3 trials
2
Actively recruiting
None scheduled
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across retatrutide and tirzepatide, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track retatrutide and tirzepatide with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Individual pipelines and other comparisons
FAQ
- How do the retatrutide and tirzepatide clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for retatrutide and 16+ for tirzepatide. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.